GlassScriptPhysician profile
Josh J White
NPI 1063478055
$3,112.87
in general payments reported to CMS, 2019-2025
27 companies · $336 in 2025
The $336 reported for 2025 was more than what a typical Medical provider received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $169 · 2022: $290 · 2023: $1,869 · 2024: $449 · 2025: $336.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $1,595 · Food and Beverage: $1,059.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $1,595.00 |
| Food and Beverage | $1,059.12 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ge Healthcare | $1,595.00 | 2023 | |
| Novartis Pharmaceuticals Corporation | $329.51 | 2022-2025 | |
| Abbott Laboratories | $127.63 | 2021-2025 | Cardiomems, Thoratec Heartmate 3 Lvas Implant Kit |
| Medtronic, INC. | $125.50 | 2021-2023 | Linq II, Micra |
| Alnylam Pharmaceuticals INC. | $97.09 | 2021-2024 | Onpattro |
| Astrazeneca Pharmaceuticals LP | $90.98 | 2021-2024 | Farxiga |
| Pfizer INC. | $84.59 | 2022-2025 | |
| Amgen INC. | $84.15 | 2022-2025 | Repatha, Repatha |
| Novo Nordisk INC | $72.76 | 2021-2025 | Wegovy, Ozempic |
| Janssen Pharmaceuticals, INC | $70.16 | 2021-2024 | Xarelto |
| Genzyme Corporation | $38.67 | 2025 | |
| Esperion Therapeutics, INC. | $37.74 | 2021 | |
| United Therapeutics Corporation | $34.49 | 2025 | Tyvaso |
| Scpharmaceuticals INC. | $34.39 | 2024 | |
| Boston Scientific Corporation | $33.00 | 2022-2023 | Watchman Access System |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $30.63 | 2023-2024 | Jardiance |
| Daiichi Sankyo INC. | $29.92 | 2024 | Injectafer |
| Amarin Pharma, INC. | $28.72 | 2021-2022 | |
| E.R. Squibb & Sons, L.L.C. | $27.64 | 2024 | Camzyos |
| Heartflow, INC. | $24.72 | 2025 | |
| Bridgebio Pharma, INC. | $21.80 | 2025 | Attruby |
| Abiomed | $19.42 | 2025 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $18.67 | 2025 | Lifevest |
| Kiniksa Pharmaceuticals International, Plc | $16.30 | 2024 | Arcalyst |
| Kiniksa Pharmaceuticals, LTD. | $14.37 | 2022 | |
| Merck Sharp & Dohme LLC | $12.71 | 2021 | |
| Chiesi USA, INC. | $12.31 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Josh White listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.